Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs 7,238
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Pipeline programs

Page 77 of 151

  1. LETROZOLE, FULVESTRANT

    Pfizer Australia Pty Ltd

    Part 2A, 2B, 2C & 2E HR-positive /HER2-negative breast cancer, Part 1F Prostate cancer, Part 2D mCRPC, Part 1A/Part 1D/Part1E Breast cancer, NSCLC, prostate, CRC, liposarcoma, or tumors with previously confirmed CDK4 or CCND1 amplification., Part 1B &1C HR-positive/HER2-negative breast cancer

    phase 2 small molecule active

    1 trial

  2. LGD-6972-5 mg

    LIGAND PHARMACEUTICALS INC

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  3. LGON-CT-002

    Lacuna Pharma Pty Ltd

    Moderate to severe hypertriglyceridemia

    phase 2 small molecule active

    1 trial

  4. LIBTAYO 350 mg concentrate for solution for infusion.

    The George Institute

    basal cell carcinoma

    phase 2 small molecule active

    1 trial

  5. LIBTAYO 350 mg concentrate for solution for infusion.

    The George Institute

    Cutaneous squamous cell carcinoma (ccSCC)

    phase 2 small molecule active

    1 trial

  6. LICSBR

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Locally Advanced Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  7. LIK066

    Novartis Pharmaceuticals

    Obese Patients With Non-alcoholic Steatohepatitis (NASH)

    phase 2 small molecule completed

    1 trial

  8. LIMBAL STEM CELLS, AUTOLOGOUS

    Fondazione Telethon ETS

    low back pain

    phase 2 small molecule active

    1 trial

  9. LM-108 antibody and sintilimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    NSCLC

    phase 2 small molecule active

    1 trial

  10. LM-302

    LaNova Medicines Limited

    Advanced Solid Tumor

    phase 2 small molecule completed

    1 trial

  11. LN-145

    Iovance Biotherapeutics B.V.

    Squamous Cell Carcinoma of the Head and Neck

    phase 2 mab completed

    1 trial

  12. LN-145

    Iovance Biotherapeutics B.V.

    Cutaneous Squamous Cell Carcinoma

    phase 2 mab active

    1 trial

  13. LN-145

    Iovance Biotherapeutics B.V.

    Cervical Carcinoma

    phase 2 mab terminated

    1 trial

  14. LN-145

    Iovance Biotherapeutics B.V.

    Non Small Cell Lung Cancer

    phase 2 mab terminated

    1 trial

  15. LN-145

    Iovance Biotherapeutics B.V.

    Metastatic Non Small Cell Lung Cancer

    phase 2 mab active

    1 trial

  16. LNA043

    Novartis Pharmaceuticals

    Osteoarthritis

    phase 2 small molecule active

    1 trial

  17. LOLA trial

    Fondazione Telethon ETS

    gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET)

    phase 2 small molecule active

    1 trial

  18. LOSARTAN

    Istituto Gentili S.r.l.

    Osteogenesis Imperfecta

    phase 2 small molecule active

    1 trial

  19. LOTS-GC-01

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastric Cancer

    phase 2 small molecule active

    1 trial

  20. LOXO-BTK-18001 BRUIN

    Wuhan Createrna Science and Technology Co., Ltd

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Non-Hodgkin Lymphoma (NHL)"

    phase 2 other active

    1 trial

  21. LOXO-RAS-20001

    Eli Lilly Co.

    KRAS G12C-Mutant Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  22. LOXO-RET-18036

    Wuhan Createrna Science and Technology Co., Ltd

    Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors

    phase 2 small molecule active

    1 trial

  23. LP-08 80mg

    LIPELLA PHARMACEUTICALS INC.

    Interstitial Cystitis

    phase 2 small molecule completed

    1 trial

  24. LP-10

    LIPELLA PHARMACEUTICALS INC.

    Hemorrhagic Cystitis

    phase 2 small molecule completed

    1 trial

  25. LP-10 (Liposomal Tacrolimus)

    LIPELLA PHARMACEUTICALS INC.

    Oral Lichen Planus

    phase 2 small molecule active

    1 trial

  26. LP-98 20 mg

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HIV

    phase 2 small molecule active

    1 trial

  27. LTI-01

    Shanghai Reinovax Biologics Co.,LTD

    Pleural Effusion

    phase 2 small molecule completed

    1 trial

  28. LTI-03

    Shanghai Reinovax Biologics Co.,LTD

    Idiopathic Pulmonary Fibrosis (IPF)

    phase 2 small molecule active

    1 trial

  29. LTI-03-2001 (RENEW)

    Shanghai Reinovax Biologics Co.,LTD

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule active

    1 trial

  30. LTS17231

    Sanofi-aventis Healthcare Pty Ltd

    Asthma

    phase 2 other active

    1 trial

  31. LTS17704

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 2 small molecule active

    1 trial

  32. LUM001

    Mirum Pharmaceuticals International B.V.

    PBC

    phase 2 small molecule completed

    1 trial

  33. LUM001

    Mirum Pharmaceuticals International B.V.

    Alagille Syndrome

    phase 2 small molecule completed

    2 trials

  34. LUM001

    Mirum Pharmaceuticals International B.V.

    Primary Biliary Cirrhosis

    phase 2 small molecule terminated

    1 trial

  35. LUM001

    Mirum Pharmaceuticals International B.V.

    Primary Sclerosing Cholangitis (PSC)

    phase 2 small molecule completed

    1 trial

  36. LUM001 (Maralixibat)

    Mirum Pharmaceuticals International B.V.

    Progressive Familial Intrahepatic Cholestasis (PFIC)

    phase 2 small molecule completed

    1 trial

  37. LUM001 (Maralixibat)

    Mirum Pharmaceuticals International B.V.

    Alagille Syndrome

    phase 2 small molecule completed

    3 trials

  38. LUMYKRAS 120 mg film-coated tablets

    The George Institute

    locally-advanced and unresectable or metastatic NSCLC with KRAS G12C

    phase 2 small molecule active

    1 trial

  39. LX1001

    BRIGHT MINDS BIOSCIENCES INC.

    Alzheimer Disease

    phase 2 mab completed

    1 trial

  40. LX1031 High Dose

    LEXICON PHARMACEUTICALS, INC.

    Irritable Bowel Syndrome

    phase 2 small molecule completed

    1 trial

  41. LX2020

    Lexeo Therapeutics

    Arrhythmogenic Cardiomyopathy

    phase 2 gene therapy active

    1 trial

  42. LX3305 low dose

    LEXICON PHARMACEUTICALS, INC.

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  43. LX4211 Low Dose

    LEXICON PHARMACEUTICALS, INC.

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  44. LX6171 High Dose

    LEXICON PHARMACEUTICALS, INC.

    Age-Related Memory Disorders

    phase 2 small molecule completed

    1 trial

  45. LX7101 (0.125%)

    LEXICON PHARMACEUTICALS, INC.

    Primary Open-angle Glaucoma

    phase 2 small molecule completed

    1 trial

  46. LX9211

    LEXICON PHARMACEUTICALS, INC.

    Diabetic Peripheral Neuropathy

    phase 2 small molecule completed

    1 trial

  47. LY2140023

    Novo Nordisk A/S

    Schizophrenia

    phase 2 small molecule terminated

    1 trial

  48. LY2157299

    Eli Lilly and Company

    Carcinoma, Hepatocellular

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.